FDA rejects Zealand Pharma's GLP-2 analog in rare bowel disease

The FDA has denied Zealand Pharma’s approval bid for glepaglutide—a possible challenger to Takeda’s Gattex—in short bowel syndrome (SBS), citing a lack of evidence.